





Development of Geriatric Oncology in France



Pr Pierre Soubeyran

Institut Bergonié, Bordeaux, France

Epidemiology

- French population, 2013
 - 9% older than 75 (10.9% females, 7% males)
- Number of cancer cases in France, 2012
 - 355 000 cases
 - 32.4% ≥ 75y (115 310 cases)
 - 10% ≥ 85y
 - In 2050: 50% ≥ 75y



Epidemiology

- Patients older than 75 hospitalised in 2013
 - 361 562 patients
 - 1 529 637 hospitalisations (24%)

	<75	>75
Community Hospital	1 268 963 (26,2%)	473 861 (36,7%)
Others (Private, ESPIC, Military)	1 387 600 (28.6%)	407 404 (31.5%)
University Hospitals	1 128 402 (23.3%)	261 699 (20,3%)
Cancer Center	1 065 288 (22%)	149 303 (11,6%)







INCa initiatives

Plan Cancer 2003 - 2008



Département de l'Amélioration de la Qualité des Soins et de l'Accès aux Innovations

Présentation de l'appel à projets national 2006

Emergence d'unités pilotes de coordination en Oncogériatrie (UPCOG)



Date limite de dépôt des dossiers Vendredi 15 septembre 2006

15 Geriatric Oncology units







Appel à projets 2011

Déploiement national d'unités de coordination en oncogériatrie-UCOG



Action 4.2 Action 23.4

UCOG - Geriatric Oncology units Objectives

Disseminate geriatric oncology practice

- In other hospitals allowed to perform cancer treatment
- Implementation of screening
- Assessment of screened patients
- Develop Geriatric Oncology research
 - Priority of the PHRC program
 - Objective: 5% patients included in clinical trials
- Promote teaching and training
- Inform patients, family and public




UCOG - Geriatric Oncology units

Objectives

Disseminate geriat

- In other hospitals all treatment

- Implementation of scree
- Assessment of screened
- Develop Geriatric Oncol
 - Priority of the PHRC prog
 - Objective: 5% patients in
- Promote teaching and to
- Inform patients, family






UCOG - Geriatric Oncology units

Objectives

op Geriatric Oncol


- Priority of the PHRC prog
- Objective: 5% patients in
- Promote teaching and to
- Inform patients, family





Funding

- Yearly funding by the INCa
 - UCOG: 250 000€ (3) or 160 000 to 200 000 (21)
 - AOG: 90 000€ (4)
 - Plus about 52 154€ for inter-regional support (5)
- Overall cost: 5 200 000€/year









Clinical research



UNICANCER GERICO

The GERICO national cooperative group



Critical Reviews in Oncology/Hematology 80 (2011) 160-170



Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial

Etienne G.C. Brain ^{a,b,*}, Cécile Mertens ^c, Véronique Girre ^d, Frédérique Rousseau ^e, Emmanuel Blot ^f, Sophie Abadie ^g, Lionel Uwer ^h, Emmanuelle Bourbouloux ⁱ, Isabelle Van Praagh-Doreau ^j, Loic Mourey ^k, Sylvie Kirscher ^l, Brigitte Laguerre ^m, Emmanuelle Fourme ^a, Sylvia Luneau ^{a,n}, Jean Genève ^b, Marc Debled ^c



GRITICAL REVIEWS IN
Oncology
Hematology
Incorporating Geriatric Oncology
www.elsevier.com/flocate/critierone.

Critical Reviews in Oncology/Hematology 76 (2010) 71-78

Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO)

F. Rousseau a,*, F. Retornaz b, F. Joly c, B. Esterni i,d, S. Abadie-Lacourtoisie e, P. Fargeot f, E. Luporsi g, V. Servent h, B. Laguerre i, E. Brain j, J. Geneve k, Programme d'Action Concertée GERIatrie on COlogie (PAC GERICO)

- The GERICO national cooperative group
- The EPOG meeting, yearly since 2005
 - Geriatric Oncology practice









- UNICANCER
 GERICO
- The GERICO national cooperative group
- The EPOG meeting, yearly since 2005
- UCOG initiatives since 2007



and Muriel Rainfray



With support of the PHRC program and INCa

original article

Annals of Oncology 22: 2325–2329, 2011 doi:10.1093/annonc/mdq748 Published online 16 February 2011

What the specific tools of geriatrics and oncology can tell us about the role and status of geriatricians in a pilot geriatric oncology program

L. Sifer-Rivière^{1*}, O. Saint-Jean², M. Gisselbrecht², T. Cudennec³ & V. Girre⁴ on behalf of Programme d'OncoGériatrie de l'Ouest Parisien (POGOP)

*Medical Emergency and Geriatric Department, Research Center of Medicine, Sciences, Health and Society (Cormés 3), EHESS, Villejuli, **Medical Emergency and Geriatric Department, Höjtal Européen Georges Prompidou (HEGP), Paiss; **Medical Genétaric Division, Höjtal Ambroise Paré, Boulogne Billancourt; **Department of Medical Oncolor, Institut Curie, Paris, **Fance

Received 18 October 2010; accepted 29 November 2010



Anne Floquet, Francois Chomy, Véronique Brouste, Alain Ravaud, Carine Bellera,




- The GERICO national cooperative group
- The EPOG meeting, yearly since 2005
- UCOG initiatives since 2007





UNICANCER

With support of the PHRC program and INCa



OPEN ACCESS

Citation: Soubeyran P. Bellera C. Govard J. Heitz

D, Curé H, et al. (2014) Screening for Vulnerability

in Older Cancer Patients: The ONCODAGE

Prospective Multicenter Cohort Study, PLoS

		Items	Possible answers (score)		
Initially	A	Has food intake declined over the past 3	0 : severe decrease in food intake		
		months due to loss of appetite, digestive problems, chewing or swallowing	1 : moderate decrease in food intake		
		difficulties?	2 : no decrease in food intake		
		Weight loss during the last 3 months	0: weight loss > 3.kg		
	В		1 : does not know 2 : weight loss between 1 and 3 kgs		
			3 : no weight loss		
		Mobility	0 : bed or chair bound		
	C		1 : able to get out of bed/chair but does not go out		
			2 : goes out		
 The GERIC 	Г		0 : severe dementia or depression		
	E	Neuropsychological problems	1 : mild dementia or depression		
THE GEIME			2 : no psychological problems 0 : BMI < 19		
	F	Body Mass Index (BMI (weight in kg) / (height in m²)	1: BMI = 19 to BMI < 21		
• The EPOG			2 : BMI = 21 to BMI < 23		
		, ,	3 : BMI = 23 and > 23		
	н	Takes more than 3 medications per day	0:yes		
	Ë	rakes more than 5 medicadons per day	1:no		
		In comparison with other people of the	0 : not as good 0.5 : does not know		
 UCOG initi 	P	same age, how does the patient consider	1: as good		
		his/her health status?	2 : better		
		Age	0:>85		
	Ш	I .	1 . 00 05		

rative group

ince 2005






en Onco-Gériatrie

UNICANCER

- With support of РПКС program and INCa

1:80-85



Muriel Rainfray^{2,16}

Olivier Saint Jean¹¹, Isabelle van Praagh⁵, Jean-Emmanuel Kurtz⁶, Stéphane Périn⁷, Jean-Luc Verhaeghe¹², Catherine Terret¹³, Christophe Desauw¹⁴

Véronique Girre¹⁵, Cécile Mertens^{1,16}, Simone Mathoulin-Pélissier^{2,3,4},



- The GERICO national cooperative group
- The EPOG meeting, yearly since 2005
- UCOG initiatives since 2007





THEN...

- SoFOG since 2013
 - French Society of Geriatric Oncology

- The GERICO national cooperative group
- The EPOG meeting, yearly since 2005

French Society of Geriatric Oncology

UCOG initiatives since 2007



SoFOG since 2013









- The GERICO national cooperative group
- The EPOG meeting, yearly since 2005
- UCOG initiatives since 2007
- THEN...
- SoFOG since 2013
 - French Society of Geriatric Oncology







UNICANCER





- The GERICO national cooperative group
- The EPOG meeting, yearly since 2005
- UCOG initiatives since 2007



SoFOG since 2013





- DIALOG in 2014
 - Geriatric OncologyIntergroup













Multi-organ clinical trials



LA LIGUE

PACAN Data Center

Tumor-oriented trials



UNICANCER Platform




DIALOG scientific objectives

- 1. Improve frailty screening strategy with G8
- 2. Evaluate impact of geriatric intervention in oncology
 - The PREPARE trial
- 3. Standardise a minimum dataset for clinical trials
- 4. Consensus endpoints for trials in older patients with cancer
- 5. Develop a common minimum database
 - Monitoring of older patients management



Screening to identify unfit patients



41% normal MGA 32% one abnormal Q

28% >1 abnormal Q


90% with abnormal MGA

Median: 3 abnormal questionnaires

10% with normal MGA



Screening to identify unfit patients



No urgent need for CGA
Standard treatment

Need for specific attention

CGA to be considered

Treatment adapted to patient's status

Improvement of G8



Available online at www.sciencedirect.com

ScienceDirect

JOURNAL OF GERIATRIC ONCOLOGY 7 (2016) 99-107



Detection of frailty in elderly cancer patients: Improvement of the G8 screening test



Aurélie Petit-Monéger^{a,b,c,*}, Muriel Rainfray^{c,d}, Pierre Soubeyran^{c,e}, Carine A. Bellera^{a,b}, Simone Mathoulin-Pélissier^{a,b,c}

Table 6 – Individual populations.	performance of	the IADL-m	odified G8	vs CGA referenc	ce standard	d from the deve	lopment and	d validation
Population	Patients with abnormal exam		Se	(95% CI)	Sp	(95% CI)	AUC	(95% CI)
	N (%)	Total						
Development Internal validation External validation	756 (80%) 394 (81%) 322 (95%)	948 ^a 486 338 ^b	77% 78% 88%	(74–80) (73–82) (84–91)	67% 71% 69%	(60–74) (60–80) (41–89)	81% 83% 90%	(78–84) (79–87) (84–95)

For the performance of the G8 modified questionnaires, sensitivity (Se), specificity (Sp), and area under the ROC curve (AUC) with 95% confidence intervals (95% CIs) are presented assuming a cut-off value of 14 (\leq 14 versus >14) and a prevalence of frailty in the ONCODAGE development population of 80%.

IADL: instrumental activities of daily living; CGA: comprehensive geriatric assessment.

- $^{\mathrm{a}}$ Development population: N = 948 patients instead of 949 patients due to missing data.
- ^b External validation population: N = 338 patients instead of 364 patients due to missing data.

Improvement of G8

- Weight loss
- Cognition/mood
- **Performance status**
- Self-rated health
- Polypharmacy

Oncologist*

Optimizing the G8 Screening Tool for Older Patients With Cancer: Diagnostic Performance and Validation of a Six-Item Version

Geriatric Oncology

CLAUDIA MARTINEZ-TAPIA, a FLORENCE CANOUI-POITRINE, a, C, SYLVIE BASTUJI-GARIN, A, C, d PIERRE SOUBEYRAN, B, C, A SIMONE MATHOULIN-PELISSIER, ^{i,j} CHRISTOPHE TOURNIGAND, ^{b,e} ELENA PAILLAUD, ^{a,f} MARIE LAURENT, ^{a,f} ETIENNE AUDUREAU, ^{a,c} ON BEHALF OF THE ELCAPA STUDY GROUP





Figure 2. Area under the ROC curve by cancer site: original versus modified G8. *, p < .05.

The PREPARE trial





Geriatric Core Dataset


Process

- Review of the literature by geriatricians
- Consensus agreement on tools by geriatricians and oncologists
- DELPHI validation by French experts
- Validation by international experts
- Includes: Social environment, ADL, IADL4, TGUG, weight loss, BMI, miniCOG, GDS4, Updated Charlson
- Objective to:
 - Standardise geriatric data collection in trials
 - Value for daily practice unknown

Consensus endpoints

A question of balance

Between two endpoints Including one highly dependent on patient's views



Choice of judgment criteria

- This is a clinical job based on
 - the chances of disease control
 - the expected benefit for the patient
- The criteria should be valid and reliable
- Clinically meaningful difference to be defined

Among the judgment criteria...


- Quality of life
 - Advantages: Pertinence in geriatric oncology
 - Limits: Difficult to measure
 - Depends on variable perceptions of patients
 - Missing data
 - Which clinically meaningful threshold to consider benefit...
- Independence
 - Advantages: Major determinant of QoL in the elderly
 - Limits: Difficult to measure
 - Missing data
 - Which clinically meaningful threshold to consider benefit...
- Overall Treatment Utility

DATECAN initiative

- International
- Consensus endpoints in Breast, sarcoma and pancreatic cancer
- Three steps
 - Review of the literature
 - Expert consensus
 - Prospective study
- DATECAN Elderly launched in 2016

Site d'investigation

Evaluation




- Among 721 academic trials in 2013
 - 72 include older patients (either specific of not)
- 5380 patients included in 2013 (4.6% of patients)




Teaching and Training

Training for G8 screening

- Among 944 accredited hospitals
- 376 cover 80% of older patients
- 342 are in contact with their UCOG
- Training performed in 173 hospitals (51%)



Six University diplomas



Six University diplomas

830 physicians trained in 2013

	Personnes for	Personnes formées (DU, DIU)	
	Nombre	%	
Oncologues	66	8 %	
Spécialistes organes	36	4 %	
Gériatres	399	48 %	
Chirurgiens	26	3 %	
Médecins généralistes	92	11 %	
Pharmaciens	85	10 %	
Radiothérapeutes	16	2 %	
IDE Hors libéraux	65	8 %	
IDE libéraux	8	1 %	
Autres personnels	37	4 %	
	830	100 %	

Continuous Professional Development

1900 physicians trained through DPC

	Personnes formées (DPC)	
	Nombre	%
Oncologues	223	12 %
Spécialistes organes	117	6 %
Gériatres	543	29 %
Chirurgiens	62	3 %
Médecins généralistes	274	14 %
Pharmaciens	37	2 %
Radiothérapeutes	37	2 %
IDE Hors libéraux	330	17 %
IDE libéraux	45	2 %
Autres personnels	233	12 %
	1901	100 %

General Overview








Organisation of patients' care


Regional cancer networks


- Accreditation of Cancer centers (number of cancer patients managed per year)
- All cancer hospitals organised in Cancer Coordination Centers (3C)
 - Multidisciplinary meetings
 - Collection of data (common CRF)











Not yet solved questions...

At the INCa level



- Inclusion of comorbidities and G8 in multidisciplinary meeting sheets
- UCOG, UCOGIR, AOG...
 - Not the final objective
 - Coordination with Cancer Regional Networks
- Fees for geriatric oncologists
 - Comprehensive Geriatric Assessment in Oncology = 23€
 - Day hospital evaluation with at least 3 Health Professionals =
 500€
- Geriatric Oncology as a priority of PHRC since 2006
 - But the number of trials sponsored by PHRC remains limited

Not yet solved questions...

- At the SoFOG level
 - National Guidelines
 - Clinical pathways





- At the UCOG level
 - Many documents have been produced by UCOGs for patients and physicians
 - To be disseminated in all UCOGs
 - Develop capacity to include in clinical trials

Not yet solved questions...



At the DIALOG level

- Develop a set of tools for clinical trials
- Develop a prospective database
- Support investigators (platforms and advice)
- Communicate with other cooperative groups to promote geriatric oncology trials











